• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?

作者信息

Autore Francesco, Visentin Andrea, Deodato Marina, Vitale Candida, Galli Eugenio, Fresa Alberto, Fazzi Rita, Sanna Alessandro, Olivieri Jacopo, Scortechini Ilaria, Del Principe Maria Ilaria, Sportoletti Paolo, Innocenti Idanna, Coscia Marta, Tedeschi Alessandra, Trentin Livio, Candoni Anna, Busca Alessandro, Pagano Livio, Laurenti Luca

机构信息

Dipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Department of Medicine, Hematology Unit, Università degli Studi di Padova, Padova, Italy.

出版信息

Blood Adv. 2025 Jan 14;9(1):162-165. doi: 10.1182/bloodadvances.2024013792.

DOI:10.1182/bloodadvances.2024013792
PMID:39454205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11754514/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12df/11754514/c1436eb458d0/BLOODA_ADV-2024-013792-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12df/11754514/c1436eb458d0/BLOODA_ADV-2024-013792-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12df/11754514/c1436eb458d0/BLOODA_ADV-2024-013792-gr1.jpg

相似文献

1
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?接受维奈克拉治疗的慢性淋巴细胞白血病患者中的 COVID-19：抗 CD20 抗体的作用是什么？
Blood Adv. 2025 Jan 14;9(1):162-165. doi: 10.1182/bloodadvances.2024013792.
2
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.维奈托克和奥滨尤妥珠单抗在慢性淋巴细胞白血病中的更新。
Future Oncol. 2021 Feb;17(4):371-387. doi: 10.2217/fon-2020-0640. Epub 2020 Oct 16.
3
Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.维奈托克单药或联合其他方案治疗复发/难治性慢性淋巴细胞白血病可达到深度和持续缓解：一项荟萃分析。
Clin Exp Med. 2022 May;22(2):161-171. doi: 10.1007/s10238-021-00739-3. Epub 2021 Jul 5.
4
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.复发或难治性慢性淋巴细胞白血病患者中维奈克拉暴露量、利妥昔单抗联合用药与无进展生存期的关系：协同作用的证明
Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16.
5
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.BCL-2 抑制作为慢性淋巴细胞白血病的治疗方法。
Curr Treat Options Oncol. 2021 Jun 10;22(8):66. doi: 10.1007/s11864-021-00862-z.
6
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma.维奈克拉在慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中不断扩大的作用。
Blood Lymphat Cancer. 2019 Mar 12;9:9-17. doi: 10.2147/BLCTT.S177009. eCollection 2019.
7
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study. Venetoclax 治疗慢性淋巴细胞白血病患者的 COVID-19 严重程度：一项单中心观察队列研究。
Ann Hematol. 2024 Aug;103(8):3053-3060. doi: 10.1007/s00277-024-05738-4. Epub 2024 Apr 18.
8
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.维奈托克联合利妥昔单抗治疗复发性慢性淋巴细胞白血病患者。
Expert Rev Hematol. 2020 Aug;13(8):885-894. doi: 10.1080/17474086.2020.1796620. Epub 2020 Jul 26.
9
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
10
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.维奈托克治疗慢性淋巴细胞白血病的疗效更新。
Expert Opin Pharmacother. 2023 May-Aug;24(11):1307-1316. doi: 10.1080/14656566.2023.2218545. Epub 2023 May 29.

本文引用的文献

1
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.慢性淋巴细胞白血病患者 COVID-19 及新冠后状况的演变：ERIC 研究，即慢性淋巴细胞白血病欧洲研究倡议。
Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29.
2
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种及替沙格韦单抗/西加韦单抗被动预防对嵌合抗原受体T细胞（CAR-T）患者的影响：来自意大利新冠疫情的三年区域经验
Bone Marrow Transplant. 2023 Dec;58(12):1394-1396. doi: 10.1038/s41409-023-02093-2. Epub 2023 Sep 4.
3
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.慢性淋巴细胞白血病患者在奥密克戎大流行期间对SARS-CoV-2疫苗的抗体反应及COVID-19易感性：一项多中心研究的两年随访
Cancers (Basel). 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993.
4
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.接种疫苗的血液系统恶性肿瘤患者突破性 COVID-19：来自 EPICOVIDEHA 调查的结果。
Blood. 2022 Dec 29;140(26):2773-2787. doi: 10.1182/blood.2022017257.
5
Tixagevimab + Cilgavimab: First Approval.替沙格韦单抗+西加韦单抗：首次批准。
Drugs. 2022 Jun;82(9):1001-1010. doi: 10.1007/s40265-022-01731-1.
6
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.mRNA 疫苗接种后非霍奇金淋巴瘤和慢性淋巴细胞白血病患者对 SARS-CoV-2 及其关注变体的体液反应。
J Clin Oncol. 2022 Sep 10;40(26):3020-3031. doi: 10.1200/JCO.22.00088. Epub 2022 Apr 18.
7
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的波兰慢性淋巴细胞白血病患者的预后
Cancers (Basel). 2022 Jan 22;14(3):558. doi: 10.3390/cancers14030558.
8
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.慢性淋巴细胞白血病患者中 SARS-CoV-2 疫苗的体液和细胞免疫原性：一项前瞻性队列研究。
Blood Adv. 2022 Mar 22;6(6):1671-1683. doi: 10.1182/bloodadvances.2021006627.
9
COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.COVID-19 疫苗在慢性淋巴细胞白血病和单克隆 B 淋巴细胞增多症中的失败；体液和细胞免疫。
Br J Haematol. 2022 Apr;197(1):41-51. doi: 10.1111/bjh.18014. Epub 2022 Jan 5.
10
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者对 mRNA 抗 COVID-19 疫苗 BNT162b2 和 mRNA-1273 的体液反应。
Blood Adv. 2022 Jan 11;6(1):207-211. doi: 10.1182/bloodadvances.2021006215.